$HSCT

Hoops Scouting USA FY 2026: Revenue $20K, Net loss $71064 EPS $(0.00) — 10-K Summary

Hoops Scouting USA reported $20,000 in revenue for FY 2026, up from $0 in FY 2025, but its net loss widened to $71,064. The company cited higher expenses for the increase, including professional and accounting fees. All revenue came from basketball merchandise sales to one customer. Management anticipates $27,000 in reporting and accounting costs over the next year and warns that operations depend on securing additional capital.

Original reporting
Published Oct 23, 2026, 9:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hoops Scouting USA FY 2026: Revenue $20K, Net loss $71064 EPS $(0.00) — 10-K Summary — source image
Decision brief

The 30-second read

$HSCTBearishLow
01

Why it matters

The filing highlights the company's reliance on a single customer and the need for additional capital, which may pressure the stock.

02

Market read

Micro‑cap earnings with modest numbers; primarily relevant to niche OTC investors.

03

What to watch

Potential hidden cash reserves or undisclosed investor commitments could mitigate financing risk.

Relevance 5/10Novelty 4/10Timing: post‑filing today

Background

Hoops Scouting USA is an OTC‑listed sports‑merchandise company that filed its FY 2026 10‑K, reporting its first revenue and a larger net loss.

Company-level read

Ticker impact

$HSCTBearishMedium confidence
Context

Hoops Scouting USA disclosed FY 2026 revenue of $20,000 and a net loss of $71,064 in its 10‑K filing.

Expected impact

likely downward pressure as investors assess financing risk

Evidence & confidence

Small revenue base and a need for additional capital suggest heightened dilution risk.

Market effects

Limited impact; reflects challenges for niche sports‑merchandise micro‑caps.

Minimal, confined to OTC market participants.

None

Counterpoint

If the company secures a strategic partnership, the loss could be a short‑term cost for long‑term upside.

Key entities

  • Hoops Scouting USA

    OTC‑listed sports‑merchandise firm reporting FY 2026 results.

Related articles

$WCNMedAI 8/10

WCN Q3 deep dive: margin expansion and sustainability initiatives drive optimism for 2027

Waste Connections (WCN) reported Q3 revenue of $2.64B, beating estimates by 1.2%, and adjusted EPS of $1.58, beating by 3.9%. The company raised its full-year revenue guidance to $10.09B. Operating margin expanded to 20.5% from 17.9% YoY. Management highlighted margin expansion from pricing discipline, landfill volume recovery, and sustainability investments, including RNG facilities. The board approved a 10% dividend increase and $1B in share repurchases.

$BEMedAI 8/10

Another AI power stock plunges 11% despite earnings beat

Bloom Energy (BE) shares fell 11% on Oct. 23 despite beating Q3 earnings estimates and raising its 2026 outlook. The company reported adjusted earnings of $0.94 per share and revenue of $1.24 billion, both above expectations. However, negative free cash flow and broader market sentiment weighed on the stock. Analysts remain divided on price targets, with JPMorgan lowering its target to $292 and Morgan Stanley raising it to $335.

$CACIHighAI 9/10

CACI Q3 deep dive: margins rise on technology mix, modest revenue miss offsets robust contract wins

CACI reported Q3 revenue of $2.47B, missing estimates by 1.4%, but beat EPS and EBITDA expectations. The company raised full-year revenue and EPS guidance. Margins improved due to higher-margin technology contracts, and backlog remained steady at $34B. Growth was driven by defense and space contracts, with new manufacturing centers supporting future production.

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.